Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.80 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.78 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.78 |
| ▸ | ACE | P12821 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.78 |
| ▸ | FAP | Q12884 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15024074 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL12323237 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL725863 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL725864 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL31268268 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Hydrochloric Acid SCHEMBL28963694 | 0.88 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 0.87 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL174489 | 0.87 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL31513245 | 0.87 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1289311 | 0.87 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227457-A1 | IMPROVED PROCESS FOR PREPARATION OF SITAGLIPTIN | AARTI PHARMALABS LIMITED (IN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227457-A1 | IMPROVED PROCESS FOR PREPARATION OF SITAGLIPTIN | AARTI PHARMALABS LIMITED (IN) | 2023-07-20 | — | — | US | disclosed |
| WO-2017006335-A1 | A PROCESS FOR PREPARING 7-[(3R)-3-AMINO-1-OXO-4-(2,4,5TRIFLUOROPHENYL)BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-1,2,4-TRIAZOLO[4,3-A]PYRAZINE PHOSPHATE MONOHYDRATE AND ITS NOVEL CRYSTALLINE FORM H | HARMAN FINOCHEM LIMITED (IN) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016162877-A1 | \"A PROCESS FOR PREPARING 7-[(3R)-3-AMINO-L-OXO-4-(2,4,5TRIFLUOROPHENYL)BUTYI]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-L,2,4-TRIAZOLO[4,3-A]PYRAZINE HYDROCHLORIDE MONOHYDRATE AND ITS CRYSTALLINE FORM\ | HARMAN FINOCHEM LIMITED (IN) | 2016-10-13 | — | — | WO | disclosed |
| US-20150148533-A1 | New Synthetic Route For The Preparation Of Beta-aminobutyryl Substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]Pyrazin-7-yl Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2015-05-28 | — | — | US | disclosed |
| US-20150148533-A1 | New Synthetic Route For The Preparation Of Beta-aminobutyryl Substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]Pyrazin-7-yl Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2015-05-28 | — | — | US | disclosed |
| EP-2477660-B1 | PHARMACEUTICAL COMPOSITION COMPRISING ACTIVE AGENTS METFORMIN AND SITAGLIPTIN OR VILDAGLIPTIN | RATIOPHARM GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-20120202820-A1 | PHARMACEUTICAL COMPOSITION HAVING THE ACTIVE SUBSTANCES METFORMIN AND SITAGLIPTIN OR VILDAGLIPTIN | RATIOPHARM GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| EP-2477660-A1 | PHARMACEUTICAL COMPOSITION HAVING THE ACTIVE SUBSTANCES METFORMIN AND SITAGLIPTIN OR VILDALIPTIN | Ratiopharm GmbH (DE) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011032912-A1 | PHARMACEUTICAL COMPOSITION HAVING THE ACTIVE SUBSTANCES METFORMIN AND SITAGLIPTIN OR VILDALIPTIN | RATIOPHARM GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
| EP-2295083-A1 | Pharmaceutical composition comprising active agents metformin and sitagliptin or vildagliptin | Ratiopharm GmbH (DE) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227457-A1 | IMPROVED PROCESS FOR PREPARATION OF SITAGLIPTIN | DPP4, DPP9, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 2/4885 |
| US-20120202820-A1 | PHARMACEUTICAL COMPOSITION HAVING THE ACTIVE SUBSTANCES METFORMIN AND SITAGLIPTIN OR VILDAGLIPTIN | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 2/4885 |
| US-20150148533-A1 | New Synthetic Route For The Preparation Of Beta-aminobutyryl Substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]Pyrazin-7-yl Compounds | GABRB3, GABRB1, GABRB2 | DPP4 40/4885DPP8 65/4885DPP9 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.